NDC 60763-482 - GLYCOPYRROLATE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 60763-482
- Package NDCs from labels
- 60763-482-02
- Manufacturer
- Stason Pharmaceuticals | Stason Pharmaceuticals, Inc. | Contract Pharmacal Corp.
- Effective date
- 2021-12-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only | Stason Pharmaceuticals | Stason Pharmaceuticals, Inc. | Contract Pharmacal Corp. | 2021-12-13 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60763-482-02 | 2025-02-17 | C162847 | 48780-1 | f386c64a-19ba-0266-e053-dadaa90a7c1a | GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only |
| 60763-482-02 | 2023-01-30 | C162847 | 48780-1 | f386c64a-19ba-0266-e053-dadaa90a7c1a | GLYCOPYRROLATE TABLETS USP 1 mg and 2 mg Rx only |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Glycopyrrolate | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | 9e5113b7-1c0c-24bd-e053-2995a90ab94b | 2023-05-09 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | bbf0abe2-8deb-19b2-e053-2a95a90a60a3 | 2023-05-08 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | b622f21f-fa37-1259-e053-2995a90aa796 | 2023-05-04 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | a2a2a03f-21cc-5fec-e053-2995a90a84cb | 2023-05-03 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | LGM PHARMA SOLUTIONS, LLC | 392a969d-1e14-4ad8-835c-a47be4983067 | 2023-04-27 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | e8bb95ed-09f1-fcf1-e053-2a95a90a93e5 | 2023-04-25 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Medical Purchasing Solutions, LLC | ea4c8be4-a1e9-5901-e053-2995a90a5e63 | 2023-04-24 | Warnings, Adverse reactions | V92SO9WP2I |
| BEVESPI AEROSPHERE | GLYCOPYRROLATE AND FORMOTEROL FUMARATE | AstraZeneca Pharmaceuticals LP | ae02436e-9528-490e-a844-0c0f6f2843f9 | 2023-03-24 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Civica, Inc. | 3ac4f32f-f5ca-4a6d-9bc7-2672d478b3d4 | 2023-03-01 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Meitheal Pharmaceuticals Inc. | 02f914a8-2356-4525-91ff-cf0c9e41ba23 | 2023-01-12 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | Quinn Pharmaceuticals | e1ded8e0-c05b-4bf4-a129-57d1726af6ed | 2022-12-20 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 26cdd84d-ffa0-4e52-b359-4acef4bd8093 | 2022-11-10 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Camber Pharmaceuticals, Inc. | 4741be85-3abb-4545-aba9-281f64d210ec | 2022-07-13 | Warnings, Adverse reactions | V92SO9WP2I |
| GLYCOPYRROLATE | GLYCOPYRROLATE | Novadoz Pharmaceuticals LLC | 98820c01-1853-45d8-9da5-875fcdf5f9ab | 2022-06-14 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Xiromed LLC | 29618edf-39b0-022a-9875-9d865450d318 | 2022-04-12 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Xiromed, LLC | f777c813-3232-d744-8bcf-58e86fb929bd | 2022-04-12 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Hikma Pharmaceuticals USA Inc. | 516cc4f8-3583-4405-ab66-29d4fcc56d05 | 2022-03-23 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Hikma Pharmaceuticals USA Inc. | d5a18d74-0d40-46e2-aa0a-41d18609a536 | 2022-03-04 | Warnings, Adverse reactions | V92SO9WP2I |
| glycopyrrolate | GLYCOPYRROLATE | BE Pharmaceuticals Inc. | d9df3900-a8c2-438b-8971-ba11ff91f90b | 2022-02-24 | Warnings, Adverse reactions | V92SO9WP2I |
| Glycopyrrolate | GLYCOPYRROLATE | Somerset Therapeutics, LLC | a46c5ec1-a1b4-46fc-9b37-8da7f0c983d6 | 2022-01-27 | Warnings, Adverse reactions | V92SO9WP2I |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.